Magnetic resonance fingerprinting (MRF) generates fast, co-registered quantitative maps from a single acquisition. This prospective study evaluates MRF-derived measures of treatment-induced T1 and T2 changes in prostate cancer patients with metastatic bone disease, by comparison with existing quantitative T1 and T2 measurements. This study demonstrated a good correlation of MRF-derived T1 and T2 changes with existing quantitative methods, supporting the use of MRF for faster measurements in bone lesions.
This abstract and the presentation materials are available to members only; a login is required.